Equiteq is pleased to announce that it has advised Alira Health, a leading international advisory firm dedicated to advancing healthcare and life sciences, on its $35M equity financing led by Creadev, an evergreen investment company backed by the Mulliez family.
Alira Health is an international advisory firm on the frontlines of healthcare transformation. They provide a suite of integrated services designed to help healthcare and life science companies innovate and grow across their solutions lifecycle.
Alira Health was founded in 1999 and is based in Framingham, MA, U.S. Offices are located in San Francisco, CA, U.S.; Paris, France; Barcelona, Spain; Munich, Germany; Milan, Italy; and Basel and Geneva, Switzerland.
Creadev is an evergreen investment firm operating worldwide, controlled by the Mulliez family, founders of one of the largest Business to Consumer retail platforms in the world. Launched in 2002 and based in Paris, with offices in New York, Shanghai, and Nairobi, Creadev invests in companies well positioned to scale and become worldwide leaders in their respective sectors.
This new partnership will help accelerate the firm’s growth strategy, focused on merging pharmaceutical, medical and digital technologies development with medical care through a patient-centric approach.
Equiteq acted as an exclusive financial advisor to Alira Health. Regarding Equiteq’s role in the transaction, CEO Gabriele Brambilla said, “We chose Equiteq based on their passion for our business and our journey, their deep knowledge of the professional services sector, and their extensive network of investor relationships. We worked closely with Equiteq to evaluate our global opportunities and select Creadev, an outstanding match for our business goals. Adam Tindall and his team understood our expectations and added value to the entire process. We would not hesitate to work with Equiteq in the future.”
Adam Tindall, MD of Equiteq, New York - USA commented, “Alira Health’s management team is doing a fantastic job of building a high growth and leading international healthcare and life sciences advisory firm. It was a pleasure working with the Alira team to find the perfect long-term partners to support their next phase of growth.”
The group of new investors will hold a minority interest in Alira Health. This support empowers the company to accelerate the development of its technology-enabled services and boost the firm's inorganic growth strategy in the U.S. and EU.